TGF-β and FRF-21: Association with IHD in patients with type 2 diabetes and obesity
Швангирадзе Т. А., Бондаренко И. З., Трошина Е. А., Никанкина Л. В., Кухаренко С. С., Шестакова М. В.
Ожирение и метаболизм
Т. 14, Вып. 3, С. 38-42
Опубликовано: 2017
Тип ресурса: Статья
DOI:10.14341/OMET2017338-42
Аннотация:
Backgraund: Obesity and type 2 diabetes mellitus (T2DM) are associated with with an increased risk of cardiovascular disease (CVD) and coronary artery disease (CAD), in particular. Obesity lead to several fibrotic processes, including activation of transforming growth factor β (TGF-β). Recent data indicate the involvement of Fibroblast growth factor 21 (FGF-21) as an important metabolic regulator, and even biomarker of metabolic changes in obesity and T2DM. Impact of metabolic dysregulation that accompany obesity and T2DM in CAD development remain a great challenge. Aims: To study TGF-β and FGF-21 level in patients with obesity and T2DM. Materials and methods: TGF-β and FGF-21 were identified in peripheral blood samples of 66 patients with obesity, aged 48-65 years. 1st group included 21 patients with CHD and T2DM; 2nd group (22 patients)- with T2DM and excluded CHD; 3rd group (20 patients) with normal glucose metabolism and excluded CHD. Results: TGF-β was lower in patients with CHD (
Ключевые слова:
Cardiovascular disease; Diabetes mellitus; Fibroblast growth factor; Obesity; Transforming growth factor β
Язык текста: Русский
ISSN: 2306-5524
Швангирадзе Т. А.
Бондаренко И. З.
Трошина Е. А.
Никанкина Л. В.
Кухаренко С. С.
Шестакова М. В. Марина Владимировна 1962-
Shvangiradze T. A.
Bondarenko I. Z.
Troshina E. A.
Nikankina L. V.
Kukharenko S. S.
Shestakova M. V. Marina Vladimirovna 1962-
TGF-β and FRF-21: Association with IHD in patients with type 2 diabetes and obesity
Текст визуальный непосредственный
Ожирение и метаболизм
Федеральное государственное бюджетное учреждение Национальный медицинский исследовательский центр эндокринологии Министерства здравоохранения Российск
Т. 14, Вып. 3 С. 38-42
2017
Статья
Cardiovascular disease Diabetes mellitus Fibroblast growth factor Obesity Transforming growth factor β
Backgraund: Obesity and type 2 diabetes mellitus (T2DM) are associated with with an increased risk of cardiovascular disease (CVD) and coronary artery disease (CAD), in particular. Obesity lead to several fibrotic processes, including activation of transforming growth factor β (TGF-β). Recent data indicate the involvement of Fibroblast growth factor 21 (FGF-21) as an important metabolic regulator, and even biomarker of metabolic changes in obesity and T2DM. Impact of metabolic dysregulation that accompany obesity and T2DM in CAD development remain a great challenge. Aims: To study TGF-β and FGF-21 level in patients with obesity and T2DM. Materials and methods: TGF-β and FGF-21 were identified in peripheral blood samples of 66 patients with obesity, aged 48-65 years. 1st group included 21 patients with CHD and T2DM; 2nd group (22 patients)- with T2DM and excluded CHD; 3rd group (20 patients) with normal glucose metabolism and excluded CHD. Results: TGF-β was lower in patients with CHD (